Cargando…
Efficacy And Safety Of Raltitrexed Plus Oxaliplatin-Based Transarterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma
OBJECTIVE: To evaluate the efficacy and safety of raltitrexed plus oxaliplatin-based transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma (HCC). METHODS: A total of 123 patients with unresectable HCC were recruited into the prospective cohort study. Raltitrex...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875237/ https://www.ncbi.nlm.nih.gov/pubmed/31819623 http://dx.doi.org/10.2147/CMAR.S217524 |
_version_ | 1783472984709660672 |
---|---|
author | Shao, Wenbo Li, Caixia Tang, Jun Song, Jinlong Li, Zixiang Sun, Jize Xu, Yili Zheng, Zhaomin Cao, Jingqin Zhang, Lei |
author_facet | Shao, Wenbo Li, Caixia Tang, Jun Song, Jinlong Li, Zixiang Sun, Jize Xu, Yili Zheng, Zhaomin Cao, Jingqin Zhang, Lei |
author_sort | Shao, Wenbo |
collection | PubMed |
description | OBJECTIVE: To evaluate the efficacy and safety of raltitrexed plus oxaliplatin-based transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma (HCC). METHODS: A total of 123 patients with unresectable HCC were recruited into the prospective cohort study. Raltitrexed plus oxaliplatin-based TACE was performed according to the traditional method at monthly intervals and was repeated for up to 4 cycles if no disease progression or intolerable toxicity occurred. The primary efficacy endpoint was overall survival (OS), and the secondary endpoints were progression-free survival (PFS) and tumor response rate. The Cox proportional-hazards regression model was used to assess the independent prognostic factors of OS. Adverse events were also observed. RESULTS: The median OS time and PFS were 623 days (95% CI: 461, 785) and 338 days (95% CI: 302, 704), respectively. The disease control rate was 95.5% (118/123). The Cox proportional-hazards regression model indicated that age, ECOG performance status and response to TACE as independent prognostic factors of OS. No treatment-related mortality occurred within 30 days of treatment procedure. The most common complications included postembolization syndrome, liver dysfunction and hematological toxicity. Grade 3 pain, transglutaminase abnormality and thrombocytopenia were observed in 16 (13%), 15 (12.2%) and 3 (2.4%) patients, respectively. No grade 4 adverse events were observed. CONCLUSION: Raltitrexed plus oxaliplatin-based TACE led to high tumor response rate and promising PFS and OS, and was considered safe and tolerable in patients with unresectable HCC. |
format | Online Article Text |
id | pubmed-6875237 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-68752372019-12-09 Efficacy And Safety Of Raltitrexed Plus Oxaliplatin-Based Transarterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma Shao, Wenbo Li, Caixia Tang, Jun Song, Jinlong Li, Zixiang Sun, Jize Xu, Yili Zheng, Zhaomin Cao, Jingqin Zhang, Lei Cancer Manag Res Short Report OBJECTIVE: To evaluate the efficacy and safety of raltitrexed plus oxaliplatin-based transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma (HCC). METHODS: A total of 123 patients with unresectable HCC were recruited into the prospective cohort study. Raltitrexed plus oxaliplatin-based TACE was performed according to the traditional method at monthly intervals and was repeated for up to 4 cycles if no disease progression or intolerable toxicity occurred. The primary efficacy endpoint was overall survival (OS), and the secondary endpoints were progression-free survival (PFS) and tumor response rate. The Cox proportional-hazards regression model was used to assess the independent prognostic factors of OS. Adverse events were also observed. RESULTS: The median OS time and PFS were 623 days (95% CI: 461, 785) and 338 days (95% CI: 302, 704), respectively. The disease control rate was 95.5% (118/123). The Cox proportional-hazards regression model indicated that age, ECOG performance status and response to TACE as independent prognostic factors of OS. No treatment-related mortality occurred within 30 days of treatment procedure. The most common complications included postembolization syndrome, liver dysfunction and hematological toxicity. Grade 3 pain, transglutaminase abnormality and thrombocytopenia were observed in 16 (13%), 15 (12.2%) and 3 (2.4%) patients, respectively. No grade 4 adverse events were observed. CONCLUSION: Raltitrexed plus oxaliplatin-based TACE led to high tumor response rate and promising PFS and OS, and was considered safe and tolerable in patients with unresectable HCC. Dove 2019-11-19 /pmc/articles/PMC6875237/ /pubmed/31819623 http://dx.doi.org/10.2147/CMAR.S217524 Text en © 2019 Shao et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Short Report Shao, Wenbo Li, Caixia Tang, Jun Song, Jinlong Li, Zixiang Sun, Jize Xu, Yili Zheng, Zhaomin Cao, Jingqin Zhang, Lei Efficacy And Safety Of Raltitrexed Plus Oxaliplatin-Based Transarterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma |
title | Efficacy And Safety Of Raltitrexed Plus Oxaliplatin-Based Transarterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma |
title_full | Efficacy And Safety Of Raltitrexed Plus Oxaliplatin-Based Transarterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma |
title_fullStr | Efficacy And Safety Of Raltitrexed Plus Oxaliplatin-Based Transarterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma |
title_full_unstemmed | Efficacy And Safety Of Raltitrexed Plus Oxaliplatin-Based Transarterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma |
title_short | Efficacy And Safety Of Raltitrexed Plus Oxaliplatin-Based Transarterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma |
title_sort | efficacy and safety of raltitrexed plus oxaliplatin-based transarterial chemoembolization in patients with unresectable hepatocellular carcinoma |
topic | Short Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875237/ https://www.ncbi.nlm.nih.gov/pubmed/31819623 http://dx.doi.org/10.2147/CMAR.S217524 |
work_keys_str_mv | AT shaowenbo efficacyandsafetyofraltitrexedplusoxaliplatinbasedtransarterialchemoembolizationinpatientswithunresectablehepatocellularcarcinoma AT licaixia efficacyandsafetyofraltitrexedplusoxaliplatinbasedtransarterialchemoembolizationinpatientswithunresectablehepatocellularcarcinoma AT tangjun efficacyandsafetyofraltitrexedplusoxaliplatinbasedtransarterialchemoembolizationinpatientswithunresectablehepatocellularcarcinoma AT songjinlong efficacyandsafetyofraltitrexedplusoxaliplatinbasedtransarterialchemoembolizationinpatientswithunresectablehepatocellularcarcinoma AT lizixiang efficacyandsafetyofraltitrexedplusoxaliplatinbasedtransarterialchemoembolizationinpatientswithunresectablehepatocellularcarcinoma AT sunjize efficacyandsafetyofraltitrexedplusoxaliplatinbasedtransarterialchemoembolizationinpatientswithunresectablehepatocellularcarcinoma AT xuyili efficacyandsafetyofraltitrexedplusoxaliplatinbasedtransarterialchemoembolizationinpatientswithunresectablehepatocellularcarcinoma AT zhengzhaomin efficacyandsafetyofraltitrexedplusoxaliplatinbasedtransarterialchemoembolizationinpatientswithunresectablehepatocellularcarcinoma AT caojingqin efficacyandsafetyofraltitrexedplusoxaliplatinbasedtransarterialchemoembolizationinpatientswithunresectablehepatocellularcarcinoma AT zhanglei efficacyandsafetyofraltitrexedplusoxaliplatinbasedtransarterialchemoembolizationinpatientswithunresectablehepatocellularcarcinoma |